Evidence map›Paper›PMID 42004032›Full record

ArticleiScience2026

Multimodal parameters for the diagnosis of putative primaries of cancer of unknown primary.

Shuangyue Pan, Jinyan Wang, Jing Liu, Simin He, Xin Liu, Xiaowei Zhang, Shiyu Jiang, Yanli Wang, Xiaoyan Zhou, Shaoli Song and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Shuangyue PanDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, No. 270, Dong An Road, Shanghai 200032, China.
Jinyan WangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, No. 270, Dong An Road, Shanghai 200032, China.
Jing LiuDepartment of Pathology, Fudan University Shanghai Cancer Center, No. 270, Dong An Road, Shanghai 200032, China.
Simin HeDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, No. 270, Dong An Road, Shanghai 200032, China.
Xin LiuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, No. 270, Dong An Road, Shanghai 200032, China.
Xiaowei ZhangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, No. 270, Dong An Road, Shanghai 200032, China.
Shiyu JiangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, No. 270, Dong An Road, Shanghai 200032, China.
Yanli WangDepartment of Pathology, Fudan University Shanghai Cancer Center, No. 270, Dong An Road, Shanghai 200032, China.
Xiaoyan ZhouDepartment of Pathology, Fudan University Shanghai Cancer Center, No. 270, Dong An Road, Shanghai 200032, China.
Shaoli SongDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, No. 270, Dong An Road, Shanghai 200032, China.
Liangping ZhouDepartment of Radiology, Fudan University Shanghai Cancer Center, No. 270, Dong An Road, Shanghai 200032, China.
Haiming LiDepartment of Radiology, Fudan University Shanghai Cancer Center, No. 270, Dong An Road, Shanghai 200032, China.
Jianfeng LuoDepartment of Biostatistics, School of Public Health, Fudan University, No. 138, Medical College Road, Shanghai 200032, China.
Zhiguo LuoDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, No. 270, Dong An Road, Shanghai 200032, China.
Silong HuDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, No. 270, Dong An Road, Shanghai 200032, China.
Hongxia WangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, No. 270, Dong An Road, Shanghai 200032, China.
Qifeng WangDepartment of Pathology, Fudan University Shanghai Cancer Center, No. 270, Dong An Road, Shanghai 200032, China.
Xichun HuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, No. 270, Dong An Road, Shanghai 200032, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Fudan cancer of unknown primary (CUP)-001 trial showed that the 90-gene assay-guided site-specific therapy (SST) can improve the survival of patients with CUP. A multidisciplinary team (MDT) for CUP explored whether multimodal parameters could improve the diagnosis of the putative primary site (PPS). The MDT adjudicated that 64 (49.2%), 22 (16.9%), 8 (6.2%), 14 (10.8%), and 4 (3.1%) patients had clues in pathology/immunohistochemistry (IHC), sentinel lymph nodes, Batson plexus, serum tumor marker patterns, and next-generation sequencing (NGS), respectively. The tumor marker was discarded because the PPS suggested by it had a less than 50% concordance rate with the PPS by the 90-gene assay or pathology/IHC. Only five patients (3.8%) had PPS diagnoses revised by the MDT. 113 (86.9%) patients were stageable as per the MDT, and the M1 stage was an independent prognostic factor for survival. In conclusion, the integration of the 90-gene assay with other multimodal parameters helps to establish a more reasonable, prognosis-related PPS diagnosis.

Indexed as

diagnosticsoncology

Identifiers

PMID42004032
PMCPMC13091557

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.